Epigenetics in metabolic dysfunction-associated steatohepatitis

被引:0
|
作者
Zhang, Yanru [1 ,2 ]
Ding, Ruike [1 ,2 ]
Hu, Liangshuo [3 ]
Liu, Enqi [1 ,2 ]
Qu, Pengxiang [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Lab Anim Ctr, Hlth Sci Ctr, Xian 710061, Peoples R China
[2] Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
MASH; Epigenetics; Liver; DNA methylation; Histone modifications; Noncoding RNA; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; LIPID-METABOLISM; NONCODING RNAS; LIVER; EXPRESSION; DIET; HEPATOCYTES; FIBROSIS; INJURY;
D O I
10.1016/j.cellsig.2025.111684
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease involving genetics, environment, and lifestyle, with the potential to progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Although the pathogenesis of MASH is not fully clear, increasing evidence has indicated that epigenetics plays an important role in the genesis and progression of MASH, during which, as drastic changes in metabolites, epigenetics undergo drastic changes. Roles of chromatin structure, chromatin accessibility, DNA methylation, histone modification, and non-coding RNAs were considered as bridges of pathogenic factors and MASH. In this review, the research progress on the epigenetics of MASH was summarized, and indepth research and therapeutic strategies based on epigenetics is expected to bring new hope to MASH patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis
    Li, Xincheng
    Ayada, Ibrahim
    Li, Pengfei
    Pan, Qiuwei
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 108 - 109
  • [2] Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
    Francque, Sven M.
    Vonghia, Luisa
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (12): : 1066 - 1067
  • [3] Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1701):
  • [4] Prediction of metabolic dysfunction-associated steatohepatitis resolution
    Loomba, Rohit
    Amangurbanova, Maral
    Bettencourt, Ricki
    Madamba, Egbert
    Siddiqi, Harris
    Richards, Lisa
    Gottwald, Mildred D.
    Feng, Shibao
    Margalit, Maya
    Huang, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S522 - S523
  • [5] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [6] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [7] Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists
    Mauricio, Didac
    Escalada, Javier
    Perez, Antonio
    Romero-Gomez, Manuel
    Cusi, Kenneth
    Younoussi, Zobair M.
    Lazarus, Jeffrey V.
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2024, 71 (04): : 149 - 151
  • [8] New and emerging treatments for metabolic dysfunction-associated steatohepatitis
    Tincopa, Monica A.
    Anstee, Quentin M.
    Loomba, Rohit
    CELL METABOLISM, 2024, 36 (05) : 912 - 926
  • [9] Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis
    Qin, Xueying
    Liu, Jingjing
    ACTA BIOMATERIALIA, 2024, 184 : 37 - 53
  • [10] The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis
    Charlton, Michael
    Tonnu-Mihara, Ivy
    Teng, Chia-Chen
    Zhou, Ziqi
    Asefaha, Feven
    Luthra, Rakesh
    Hoovler, Anthony
    Uzoigwe, Chioma
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 919 - 930